Unveiling the Rutgers Liver Cancer Breakthrough

The latest research from Rutgers University has brought a promising new perspective to liver cancer prevention and management. Scientists at Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center, have demonstrated that a simple dietary adjustment—reducing protein intake—can significantly slow tumor growth in livers with compromised function. This finding, detailed in a study published in Science Advances, highlights how everyday nutrition could play a pivotal role in combating hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

Led by distinguished professor Wei-Xing Zong from the Rutgers Ernest Mario School of Pharmacy, the study shifts focus from traditional treatments to metabolic vulnerabilities in cancer cells. For patients with underlying liver conditions like non-alcoholic fatty liver disease (NAFLD) or cirrhosis, this could mean a non-invasive way to lower risk or delay progression. As liver cancer cases rise in the United States—projected at 42,340 new diagnoses and 30,090 deaths in 2026—this research arrives at a critical time.

Understanding Hepatocellular Carcinoma and Its Risk Factors

Hepatocellular carcinoma (HCC), the predominant form of liver cancer, often develops in livers scarred by chronic damage. In the U.S., cirrhosis precedes about 80-90% of cases, frequently stemming from NAFLD, hepatitis B or C viruses, excessive alcohol consumption, obesity, and type 2 diabetes. NAFLD alone affects roughly one in four American adults, fueling a surge in HCC incidence despite declines in viral hepatitis-related cases.

The five-year survival rate for liver cancer hovers around 22%, underscoring the need for preventive strategies. Unlike many cancers, HCC frequently arises in non-cancerous chronic liver disease, making early intervention key. Rutgers researchers zeroed in on how metabolic stress from impaired liver function accelerates this transition, particularly through nitrogen waste management.

The Metabolic Mechanism: Ammonia Buildup Fuels Tumors

Protein breakdown produces ammonia, a toxic byproduct normally detoxified by the liver's urea cycle enzymes (UCEs)—such as carbamoyl-phosphate synthase 1 (CPS1), argininosuccinate synthase 1 (ASS1), argininosuccinate lyase (ASL), and arginase 1 (ARG1). These enzymes convert ammonia into urea for urinary excretion. In HCC and precursor conditions, UCE expression is repressed, often by oncogenic pathways like β-catenin activation, leading to hyperammonemia.

This excess ammonia doesn't just accumulate harmlessly; it gets shunted into biosynthetic pathways. Tumors exploit it to synthesize amino acids (like glutamine via glutamate dehydrogenase) and nucleotides (pyrimidines via carbamoyl phosphate diversion), essential building blocks for rapid proliferation. Rutgers experiments with 15N-labeled ammonia tracers confirmed heightened pyrimidine incorporation in tumor cells from impaired livers.

"The clinical observation that the liver’s ammonia-handling machinery is usually impaired in liver cancer patients is decades old," notes Zong. "The question that has remained unanswered until now is whether this impairment... is a driver of the tumor growth." Their work establishes causality: defective UCEs promote oncogenesis.

Experimental Design: Mouse Models Reveal Causal Links

To test this, Rutgers team used multiple HCC mouse models, including diethylnitrosamine (DEN)/phenobarbital (PB) chemical induction and genetic c-MET/β-catenin activation. They selectively silenced UCEs using CRISPR in c-MET/sgAxin1 models, where baseline UCEs remain intact.

Mice with UCE knockdown showed elevated plasma and liver ammonia, heavier tumor burdens (increased liver weight), accelerated proliferation (Ki67 markers), fibrosis, and shortened survival. Metabolomics revealed reprogrammed pathways: depleted urea cycle intermediates, enriched non-essential amino acids, TCA cycle shifts, and pyrimidine surges.

Crucially, a low-protein diet (LPD, ~6% calories from protein) versus control diet (CD, standard) or high-protein diet (HPD) dramatically intervened. LPD-fed mice had reduced ammonia, tempered UCE repression, slower tumor growth, less fibrosis/mTOR activation, and prolonged survival in both DEN/PB and c-MET/β-catenin models. Single-nucleus RNA sequencing confirmed LPD normalized hepatocyte gene signatures.

Photo by Aleksander Saks on Unsplash

Key Findings: Low-Protein Diets Extend Survival

• Mice on LPD exhibited 50-70% slower tumor progression and doubled median survival in aggressive models.
• Ammonia levels dropped significantly, blocking tumor-fueling metabolites.
• No adverse effects on body weight or healthy liver function; benefits specific to impaired livers.
• High-protein exacerbated growth, validating protein as a modifiable risk factor.

These results position dietary protein restriction as a feasible adjunct strategy, especially since LPD is simple and cost-effective.

Implications for U.S. Patients with Chronic Liver Disease

Over 4.5 million Americans live with chronic liver disease, with NAFLD prevalence at 25-30%. Cirrhosis elevates HCC risk 75-fold. For these at-risk groups, LPD could mitigate hyperammonemia—a common issue in decompensated cirrhosis.

However, caution is warranted: Cirrhosis patients often face malnutrition and sarcopenia, traditionally managed with 1.2-1.5 g/kg/day protein. Severe restriction risks frailty, especially during treatment. Zong advises: "Reducing the protein consumption may be the easiest way to get ammonia levels down," but under medical supervision, monitoring ammonia, nutrition status, and muscle mass.

Plant-based proteins may offer advantages, producing less ammonia than animal sources. Ongoing trials will clarify optimal thresholds for humans.

Rutgers Cancer Institute: Leading U.S. Liver Cancer Research

Rutgers Cancer Institute spearheads innovative metabolism-focused oncology. Zong's Cancer Metabolism and Immunology Program explores nutrient dependencies in tumors, aligning with NCI priorities. This study exemplifies Rutgers' translational impact, bridging lab discoveries to patient care.

As a hub for higher education in New Jersey, Rutgers attracts top talent in biomedical research. For aspiring researchers, opportunities abound in pharmacology and cancer biology.

Balancing Nutrition: Safety of Low-Protein Diets in Liver Disease

While promising, LPD isn't one-size-fits-all. In cirrhosis, protein restriction was historically used for hepatic encephalopathy (HE) but is now discouraged due to malnutrition risks. Guidelines (AASLD, EASL) recommend 1.2-2.0 g/kg/day, favoring branched-chain amino acids (BCAAs) for HE.

For pre-cirrhotic NAFLD or mild impairment without HE, moderate reduction (0.8-1.0 g/kg) may be safe, monitored via ammonia levels and bioimpedance. Vegans/vegetarians naturally consume less animal protein, potentially conferring protection. Clinical trials are needed to validate mouse data in humans.

Photo by Nature Zen on Unsplash

Future Directions: From Bench to Bedside

Rutgers plans human cohort studies tracking protein intake, ammonia, and HCC incidence in NAFLD/cirrhosis patients. Potential combos: LPD + urea cycle supplements (e.g., phenylbutyrate) or glutaminase inhibitors to starve tumors.

Broader implications for metabolic cancers. As U.S. obesity drives NAFLD-HCC, public health campaigns could promote balanced protein amid liver health awareness.

Wei-Xing Zong emphasizes personalization: "Any dietary changes should be discussed with a physician."

Actionable Insights and Next Steps for At-Risk Individuals

Consult hepatologists/nutritionists for ammonia testing and tailored plans. Track via apps, prioritize veggies, legumes over red meat. Muscle-preserving exercise complements diet.

For academics/professionals eyeing cancer research, Rutgers exemplifies opportunity. Platforms like Rate My Professor offer insights into faculty, while higher ed jobs list openings. Explore career advice for thriving in research.

This Rutgers study illuminates diet's power in oncology, offering hope for millions at risk.